Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. on May 12, 2020, covering events occurring on May 11, 2020. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Newark, California. The report details a significant capital raising event via a public offering of common stock.
Key Financial Metrics
The filing focuses on a specific underwriting agreement rather than periodic financial performance metrics such as revenue, profit, or operating cash flow. Key financial figures related to the offering include:
- Shares Offered: 7,000,000 shares of common stock.
- Public Offering Price: $14.00 per share.
- Price to Company: $13.16 per share (net of underwriting discounts).
- Expected Gross Proceeds: Approximately $98.0 million.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 1,050,000 additional shares.
- Maximum Potential Proceeds: Approximately $112.7 million if the over-allotment option is fully exercised.
The filing text does not provide clear values for the company's current debt levels, liquidity position, or operating margins outside the context of this transaction.
Material Changes
The primary material change reported is the execution of an underwriting agreement with Jefferies LLC and BMO Capital Markets Corp. This transaction represents a significant increase in the company's equity capital base. The offering is expected to close on May 14, 2020, subject to customary closing conditions.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or specific risk factors beyond standard underwriting terms. The transaction is being made pursuant to an effective registration statement on Form S-3 (No. 333-234414). The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions. The description of the agreement's terms is qualified by reference to the full agreement filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the final closing date of the offering (expected May 14, 2020) and whether the over-allotment option was exercised.
- Review the final prospectus supplement for specific details on the use of proceeds.
- Confirm the exact number of shares issued and the final net proceeds after deducting all offering expenses.
- Check subsequent filings for any dilution impact on existing shareholders.